Joe Stringer

Exec Chair & Director of EMEA Corporate Development

2023 - Current

Investor and Non Executive Director

2022 - 2023

Automata was founded with a clear aim: to unlock human potential with automation. Through our collaboration with some of the world’s leading pathology labs, we’ve developed the most comprehensive lab automation platform on the market. By simplifying environments and empowering people, Automata enables labs to scale with precision and creates new opportunities for scientists to accelerate innovation. https://automata.tech/

Investor Director

2024

Lightship believe clinical research can be built to improve health equity globally. Learning if treatments are safe and effective for the people who need them requires us to offer studies that are more accessible and offer choice. Lightship was founded in 2018 with the inspiration to keep people at the heart of our work and use the latest innovations in digital health, technology, and remote care melded with high quality clinical research to transform clinical trials. The Lightship approach offers clinical trials that are designed from the beginning to make it easier for patients and caregivers to take part. By using inclusive technology, flexible visit types, an amazing experience, and commitment to quality, we can develop programs to better bring new potentially life-saving therapies into the world, together.

Non Executive Director & ESG Committee

2023

One of the world’s leading health and wellness retailers and the largest in Europe, with over 1,300 stores in 16 countries and a strong online offer. PE-backed, by L1 Retail. In addition to providing formal NED governance and scrutiny, I am supporting the H&B Exec team to support their digital and transformation activities on their journey to a leading global wellness destination, adding quality years to life. The H&B team are focused on a hugely ambitious vision to improve the wellness of millions of people around the world. I am providing support to a number of fucntions across the business, in particular Strategy, Transformation, M&A/Investments, ESG, the Group Science and Medical function and the Wellness Futures business line, which incubates and scales new propositions around wellness services and solutions through a combination of venture-building and partnerships.

Board Advisor

2023

Talking with patients is the basis of all healthcare. Ufonia combines AI and clinical evidence to automate routine telephone consultations. Ufonia's technology makes care more convenient, reliable and consistent for patients; increases hospitals’ capacity; and allows clinical professionals to spend more time meeting patients’ needs.

Investor in residence

2023

Establishing a new £500m investment vehicle with a focus on providing growth and scaling capital to businesses that drive positive social impact while delivering returns to investors. Particular interest in solutions that support preventative health, levelling-up health inequalities and providing employment pathways to underserved communities.

Investment Committee / Advisor

2023

Macmillan exists to help improve the lives of people with cancer in the UK. They are a source of support, helping anyone affected by cancer navigate through the system to get what they need and a force for change, working to improve cancer care. The future experience for people with cancer will be fundamentally different to what it is today. There are huge opportunities in medical technology, cancer services innovation, and system change that could significantly improve how people are diagnosed and treated, as well as how cancer is managed as a long-term condition. There are, however, huge challenges ahead, from lack of funding to workforce shortages and inequity of care. Investing money in the right way to deliver the most impact is not only a vital part of Macmillans 100-year history but their future too. The Macmillan Innovation Impact Investment Portfolio was launched at the beginning of 2023 and is a new way for Macmillan to invest in ground-breaking innovations in cancer care. It is a test and, therefore, relatively modest: investing £ 3.5 million over the next two years in the most innovative ideas and pioneering cancer products.

Investor & Board advisor

2023

METTLE is the digital toolkit for men's minds. The app that gives men the permission and tools they need to look after their mental health. Currently in seed fundraising round in stealth mode but big news soon...

Investor & Board advisor

2023

www.musichealth.ai - Empowering humans to become the superheroes of their brain health using the power of music - initially in dementia care

Investor & Board advisor

2023

Recent winners of the London Tech Week pitch contest - Symbiotex are a seaweed based, home compostable rigid and semi-rigid biomaterials company focused on lowering the carbon footprint of the medical devices industry.

Board of Advisors

2023

Advise Inc bring visibility to healthcare supply chains - they are the go-to platform for price and value chain analysis in the UK/ NHS